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Fabry disease (FD) is an inherited metabolic disorder caused by partial or full inactivation of the lysosomal hydrolase 훼-
galactosidase A (훼-GAL).The impairment of 훼-GAL results in the accumulation of undegraded glycosphingolipids in lysosomes
and subsequent cell and microvascular dysfunctions.This study reports the clinical, biochemical, and molecular characterization
of 15members of the same family. Eight members showed the exonic mutation M51I in the GLA gene, a disease-causing mutation
associated with the atypical phenotype. The clinical history of this family highlights a wide phenotypic variability, in terms of
involved organs and severity. The phenotypic variability of two male patients is not related to differences in 훼-GAL enzymatic
activity: though both have no enzymatic activity, the youngest shows severe symptoms, while the eldest is asymptomatic. It is
noticeable that for two female patients with the M51I mutation the initial clinical diagnosis was different from FD. One of them
was diagnosed with Familial Mediterranean Fever, the other with Multiple Sclerosis. Overall, this study confirms that the extreme
variability of the clinical manifestations of FD is not entirely attributable to different mutations in the GLA gene and emphasizes
the need to consider other factors or mechanisms involved in the pathogenesis of Fabry Disease.
1. Background
Anderson-Fabry disease is a metabolic lysosomal storage
disorder caused by the functional deficit of the enzyme훼-galactosidase A (훼-GAL A) [1]. This deficit alters the
metabolism of some glycosphingolipids, mainly globotriao-
sylceramide (Gb3), that accumulate in lysosomes ofmany cell
types [2]. FD is an X-linked lysosomal enzymopathy caused
by mutations in the GLA gene coding for 훼-GAL A located
on the long arm of the X Chromosome (Xq22.1) [3]. To date,
more than 1000 mutations were described in the GLA gene’s
exons and introns and discrimination between pathological
and neutral mutations is difficult (http://fabry-database.org/,
June 2013) [4, 5]. Gb3 and other neutral glycolipids gradually
accumulate in endothelial cells, smooth muscle cells in blood
vessels, renal epithelial cells, pericytes, myocardial cells, neu-
rons of the spinal cord, and neurons of the dorsal root ganglia;
this leads progressively to cellular dysfunction, necrosis,
apoptosis, inflammation, fibrosis, and poor target-organs
perfusion. Clinical manifestations are more severe in male
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hemizygous subjects than in female heterozygotes subjects,
often asymptomatic, according to Mary Lyon’s hypothesis of
random inactivation of the X Chromosome [6]. Recently it
was found that also women can show severemanifestations of
FDwith irreversible organ damage, thus excluding the theory
that women are exclusively carriers of the disease. For this
reason, an accurate follow-up is required for female patients,
independently from enzymatic activity levels.
The clinical manifestations of the disease appear in child-
hood; harmful, renal, cardiac, and cerebrovascular compli-
cations usually arise in the adulthood. The selective damage
of tubular epithelial cells and glomerular epithelial cells
in FD patients often causes chronic kidney disease that
progresses to end-stage renal disease (ESRD)with age [7].The
enzyme replacement therapy (ERT) is the current treatment
available for Fabry patients that reduces Gb3 levels and
prevents further accumulation [8]. Although the ERT blocks
the progression of the disease in most of the cases, it is
not able to limit some specific symptoms and to eradicate
the disease [9–11]. A reliable and early diagnosis of Fabry
disease is still hard to perform. Retrospective studies found
a significant delay of the diagnosis of Fabry disease in about
40% of males and 70% of females [12]. In particular, the time
elapsing between the onset of first signs and symptoms and
the correct diagnosis is 13 years for male patients and 17 years
for female patients [13]. Probably the difficulties in diagnosis
make the impact of the disease hard to assess; the incidence
in the general population is estimated at 1 : 40,000, but
recent initiatives of neonatal screening found an incidence
of 1 : 3,100 born in Italy [14] and 1 : 1,500 in newborns in
Taiwan [15]. FD is underestimated mainly because its clinical
manifestations can be confused with those of other systemic
diseases. For this reason, FD is often treated as single organ
pathology. In literature there are cases in which the clinical
indicators of FD overlap those of some rheumatic disorders,
such as Familial Mediterranean Fever (FMF). In effect, these
two diseases share not only the first symptoms, but also
the clinical manifestations; the first signs appear during
childhood, with recurrent episodes of fever, abdominal and
joint pain, gastrointestinal disorders, and kidney damage. FD
often involves also the central nervous system causingmicro-
and macroangiopathy in the brain. Because of these features
and the frequent presence of lesions inMRI scans, FD is often
misdiagnosed as Multiple Sclerosis [16]. In this paper, we
report the study of an interesting family group and our results
confirm several critical issues related to FD and probably
evoke new questions.
2. Patients and Methods
2.1. Patients. Peripheral blood samples were collected, using
EDTA as an anticoagulant, for genetic analysis and detection
of 훼-galactosidase A activity.
2.2. DNA Isolation. DNA samples were isolated from whole
blood by column extraction (GenElute Blood Genomic DNA
Kit, Miniprep, Sigma-Aldrich, USA), and their concentra-
tions were determined using a spectrophotometer.
2.3. HRM Analysis and DNA Sequencing. A presequencing
screening was performed on DNA samples by High Resolu-
tionMelting (HRM) analysis for the study of the exons of the
GLA gene and their flanking regions; the Light Cycler 480
system (Roche Applied Science, Germany) was used. PCR
products presenting melting curves different in position or
shape from those of the wild type control were sequenced
to identify the suspected mutations. Purified PCR products
were sequenced using the automatedDNA sequencer at BMR
Genomics.
2.4. 훼-Galactosidase A Activity Assay. The activity of 훼-
galactosidase A was determined by the Dried Blood Filter
Paper test described by Chamoles et al., with minor modi-
fications [17].
3. Results and Discussion
This study reports the clinical, biochemical, and molecular
characterization of 15members of the same family.The pedi-
grees of the family are shown in Figure 1 and relevant enzy-
matic and molecular data are given in Table 1.The molecular
analysis of the GLA gene revealed the known M51I mutation
in 8 patients aged from 22 to 58 years (mean 34.6±15.96) [14]
as in Figure 2. A young 22-year-old female patient (case 4:1)
came at our attention because during her childhood she had
suffered from recurrent fever of unknown origin, burning
pain in hands and feet, and gastrointestinal disturbances. She
underwent several instrumental and genetic tests that led to
the clinical diagnosis of FMF.This diagnostic hypothesis was
not supported by the genetic analysis of the MEFV gene,
showing a single heterozygous mutation (A744S).Therefore,
Fabry disease was considered for diagnosis.The genetic anal-
ysis of the GLA gene was performed and the M51I mutation
was identified. Ten years after the appearance of the first
clinical manifestations, the definitive diagnosis was made:
Fabry disease. The patient harboring a pathogenic mutation
showed an enzymatic activity of 2.6 nmol/h/spot, below the
normal values. Genetic and biochemical tests were extended
to proband family members. These analyses showed that
the proband inherited the M51I mutation from her mother
(case 3:1). She is a 56-year-old woman with the enzymatic
activity slightly above normal values and with symptoms not
clearly related to FD.The proband’s father (case 3:2) showed
neither mutations nor symptoms and normal enzymatic
activity (3.5 nmol/h/spot).The maternal aunt of the proband
(case 3:3) was found to carry the same mutation and her
enzymatic activity was 2.9 nmol/h/spot, below normal range.
This 53-year-old woman, unlike her sister (case 3:1), showed
cardiac involvement with dyspnea and arrhythmias. More
severe symptoms affected the children of case 3:3, who are
actually cousins of the proband. Among them, a young
woman aged 21 (case 4:5) with the M51I mutation and low
enzymatic activity (2 nmol/h/spot) showed angiokeratomas
and moderate proteinuria; case 4:3 is a young man aged 28
with the M51I mutation, no enzymatic activity, and showing
a serious cerebrovascular involvement. Another member of
this family with no enzymatic activity is case 3:7 that is
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Figure 1:The family tree/pedigree.
Table 1: GLA genetic diagram of family studied.
Patient number Kinship Gender/age GLA mutation Enzyme activity (nmol/h/spot)
2:2 Grand mother F/84 — —
2:3 Sister of 2:2 F/77 — 3.1
3:1 Mother F/56 M51I 3.3
3:2 Father M/53 — 3.5
3:3 Aunt F/53 M51I 2.9
3:5 Cousin of 3:1 M/64 — 2.3
3:7 Cousin of 3:1 M/58 M51I 0.3
4:1 Proband F/22 M51I 2.6
4:2 Brother M/27 — 5.5
4:3 Cousin M/28 M51I 0
4:4 Cousin M/25 — —
4:5 Cousin F/21 M51I 2
4:6 Daughter of 3:5 F/24 — 5.4
4:7 Daughter of 3:7 F/22 M51I 2.4
4:8 Daughter of 3:7 F/25 M51I 0
—, no mutation; F, female; M, male. Normal values of 훼-Gal-A activity assayed in whole blood are >3 nmol/h/spot.
the cousin of the proband’s mother (case 3:1). Although
this 58-year-old man carries the same mutation found in
his relatives, he is completely asymptomatic. This man’s
daughters also inherited the M51I mutation; the 22-year-old
daughter (case 4:7) had the 훼-galactosidase A activity below
normal range (2.4 nmol/h/spot); the other daughter aged 25
(case 4:8) had no enzymatic activity, a rare condition for
female subjects, and was also diagnosed as affected by Mul-
tiple Sclerosis based on the presence of lesions of the corpus
callosum on MRI. Noteworthy is that the brother (case 3:5)
of case 3:7 had lower than normal enzymatic activity
(2.3 nmol/h/spot), though he had neither genetic alteration
in the GLA gene nor symptoms referable to Fabry disease.
4. Conclusions
Fabry disease is a lysosomal storage disorder with the gly-
cosphingolipid metabolism deeply compromised.
The defect of 훼-galactosidase A leads to the progressive
accumulation of globotriaosylceramide in parenchyma cells
of various organs and in endothelial cells. This pathology is
believed to be rare, but it should be considered uncommon,
little known, according to results from literature [13]. Fabry
Disease is still hard to diagnose because of its features and
because it has clinical manifestations overlapping to other
pathologies and subsequently a wide range of differential
diagnoses that involve several clinical specialties [18]. In
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Figure 2: Mutation p.M51I: (a) HRM analysis of exon 1 of the GLA gene in male patients (curves indicated by the dashed arrow) and in
a healthy control (curves indicated by the solid arrow); (b) portion of the electropherogram of exon 1 of the GLA gene in male patients in
which p.M51I mutation is indicated by the arrow; (c) portion of the sequence of exon 1 of the GLA gene in male patients aligned with the
corresponding sequence of a healthy control (wt).
particular, subjects affected by the atypical form of the
disease are harder to diagnose than subjects with the classic
phenotype. In this study we report the clinical, biochemical,
and molecular study of 15 members of the same family. In
addition to the proband, seven subjects showed alterations
in the GLA gene. This aspect highlights the importance of
pedigree analysis in families with FD for identifying other
possibly affected relatives [19]. Precisely the genetic analysis
revealed the M51I mutation, which is considered pathogenic
and related to the atypical variants of the disease [14, 20].
The M51I mutation is a G to A transition at the codon 51
that causes the substitution between two nonpolar amino
acids: Methionine and Isoleucine. Molecular models of this
mutated protein showed that this mutation does neither
alter the active site of 훼-galactosidase A nor interfere with
the enzyme catalytic activity, but it could alter the enzyme
stability [21]. The analysis of this family confirmed that for
this disorder there is little genotype-phenotype correlation,
even at intrafamiliar level, and that it can cause a constellation
of symptoms, often overlapping to different pathologies.
These critical features of Fabry disease frequently cause
misdiagnosis, delay in the correct diagnosis, and difficulties
in prognosis. The current pathogenic theory of FD is based
on the fact that the GLA gene is the only one associated
with this disorder and that the defect in 훼-galactosidase A
is responsible for the accumulation of GB3 in lysosomes and
for the subsequent cell damage and clinical symptomatology.
Symptoms variability could be related to the residual enzyme
activity in nonclassic FD patients and to the progression
of FD, whose clinical manifestations get worse over time.
Nevertheless, this theory is contradicted by some cases found
in this and other studies [22, 23]. Particular is the case of
the two male members of this family hemizygous for the
M51I mutation. Though both have no enzymatic activity,
they show different clinical manifestations; the youngest (28
years old) has more severe symptoms than the eldest (58
years old), who is asymptomatic. Therefore, considering the
current pathogenic theory, it is hard to explain the absence
of symptoms in a patient with no enzymatic activity and
his survival over the fifth decade of life. The penetrance
of different GLA mutations could be influenced by the
interindividual variability of other genetic and epigenetic
factors or by differences in environmental conditions. It is
still not clear if the extreme phenotypic disease variability and
the involvement of different target organs could be explained
with these processes individually or taken together [24].
Further investigations are required to understand the reasons
for this variability to improve the accuracy of the prognosis
and diagnosis of FD.
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